Adenosine A 2A and A 2B receptor expression in neuroendocrine tumours: Potential targets for therapy

Purinergic Signalling

Volumn 8, Issue 2, 2012, Pages 265-274

  Kalhan, A ^a   Gharibi, B ^a   Vazquez, M ^a   Jasani, B ^a   Neal, J ^a   Kidd, M ^b   Modlin, I M ^b   Pfragner, R ^c   Rees, D A ^a   Ham, J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

A 2A adenosine receptor; A 2B adenosine receptor; Adenosine; Cell proliferation; Chromogranin A; Human neuroendocrine tumours

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; CHROMOGRANIN A; CYCLIC AMP; ADENOSINE RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT;

ARTICLE; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING; BIOSYNTHESIS; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROENDOCRINE TUMORS; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B;

EID: 84861013765     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-011-9280-5     Document Type: Article

References (45)

1. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R et al (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17: 600-606.
2. Arnold R, for the PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Orthod 27(28): 4656-4663. doi: 10. 1200/JCO. 2009. 22. 8510, ASCO GI Cancers Symposium.
3. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Brit J Cancer 92: 1493-1498.
4. Saras J, Gronberg M, Stridsberg M, Oberg KE, Janson ET (2007) Somatostatin induces rapid contraction of neuroendocrine cells. FEBS Lett 581: 1957-1962.
5. Oberg K (1994) Biology, diagnosis and treatment of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Oncol 6: 441-451.
6. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z et al (2007) Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumours. Cancer 109: 1478-1486.
7. Modlin IM, Moss SF, Oberg K, Padbury R, Hicks RJ, Gustafsson BI et al (2010) Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Australia 193: 46-52.
8. Bruick RK (2003) Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Gene Dev 17: 2614-2623.
9. Adair TH (2005) Growth regulation of the vascular system: an emerging role for adenosine. Am J Physiol-Reg I 289: R283-R296.
10. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E et al (2006) Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol 72: 19-31.
11. Ryzhov S, McCaleb JL, Goldstein AE, Biaggioni I, Feoktistov I (2007) Role of adenosine receptors in the regulation of angiogenic factors and neovascularisation in hypoxia. J Pharmacol Exp Ther 320: 565-572.
12. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz K-N, Linden J (2001) Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552.
13. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG et al (2003) A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Therapeut 100: 31-48.
14. Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5: 247-264.
15. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA (2011) Adenosine receptors and cancer. Biochim Biophys Acta 1808: 1400-1412.
16. Pfragner R, Wirnsberger G, Niederle B, Behmel A, Rinner I, Mandl A et al (1996) Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I): characterization and effects of 5-azacytidine on proliferation. Int J Oncol 8: 513-520.
17. Modlin IM, Kidd M, Pfragner R, Eick GN, Champaneria C (2006) The functional characterization of normal and neoplastic enterochromaffin cells. J Clin Endocr Metab 91: 2340-2348.
18. Kidd M, Eick GN, Modlin IM, Pfragner R, Champaneria MC, Murren J (2007) Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J Mol Endocrinol 38: 181-192.
19. 2B adenosine receptors. Endocrinology 143: 2427-2436.
20. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C et al (2007) Caffeine inhibits adenosine-induced accumulation of HIF-1α, VEGF and IL-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 72: 395-406.
21. Lu J, Pierron A, Ravid K (2003) An adenosine analogue, IB-MECA, down-regulates estrogen receptor alpha and suppresses human breast cancer cell proliferation. Cancer Res 63: 6413-6423.
22. 3 adenosine receptor agonist CF101. Brit J Cancer 89: 1552-1558.
23. Panjehpour M, Karami-Tehrani F (2007) Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. Oncol Res 16: 575-585.
24. Saito M, Yaguchi T, Yasuda Y, Nakano T, Nishizaki T (2010) Adenosine suppresses CW2 human colonic cancer growth by inducing apoptosis via A(1) adenosine receptors. Cancer Lett 290: 211-215.
25. Mirza A, Basso A, Black S, Malkowski M, Kwee L, Pachter JA et al (2005) RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis. Cancer Biol Ther 4: 1355-1360.
26. Christofi FL, Kim M, Wunderlich JE, Xue J, Suntres Z, Cardounel A et al (2004) Endogenous adenosine differentially modulates 5-hydroxytryptamine release from a human enterochromaffin cell model. Gastroenterology 127: 188-202.
27. Spychala J (2000) Tumor-promoting functions of adenosine. Pharmacol Therapeut 87: 161-173.
28. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F (2008) Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 3: e2599.
29. Stagg J, Smyth MJ (2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29: 5346-5358.
30. Li S, Huang S, Peng SB (2005) Overexpression of G-protein-coupled receptors in cancer: involvement in tumor progression. Int J Oncol 27: 1329-1339.
31. ++ signal. Brit J Pharmacol 145: 211-218.
32. 2B receptor is highly expressed in human hepatocellular carcinoma. Hepatol Res 36: 56-60.
33. Rodrigues S, de Wever O, Bruyneel E, Rooney RJ, Gespach C (2007) Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis. Oncogene 26: 5615-5625.
34. Ryzhov S, Novitskiy SV, Zaynagetdinov R, Goldstein AE, Carbone DP, Biaggioni I et al (2008) Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia 10: 987-995.
35. 2A adenosine receptor protects tumors from antitumor T cells. P Natl Acad Sci USA 103: 13132-13137.
36. Lukashev D, Sitkovsky M, Ohta A (2007) From "Hellstrom Paradox" to anti-adensinergic cancer immunotherapy. Purinerg Signal 3: 129-134.
37. 2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Neuropsychopharmacol 28: 1317-1327.
38. Srirajaskanthan R, Watkins J, Marelli L, Khan K, Caplin ME (2009) Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology 89: 308-314.
39. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D et al (2010) Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. P Natl Acad Sci USA 107: 1547-1552.
40. 2A isoform) and ERalpha mediates ethanol action in MCF-7 breast cancer cells. Oncol Rep 21: 977-981.
41. Mujoomdar M, Hoskin D, Blay J (2003) Adenosine stimulation of the proliferation of colorectal carcinoma cell lines. Roles of cell density and adenosine metabolism. Biochem Pharmacol 66: 1737-1747.
42. 3H]thymidine assay system and modulatory effects of the cellular microenvironment in vitro. J Cell Physiol 201: 429-438.
43. Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL (2004) Clinical significance of elevated serum chromogranin A levels. Scand J Gastroentero 39: 969-973.
44. Oberg K, Eriksson B (2005) Endocrine tumours of the pancreas. Best Pract Res Cl Ga 19: 753-781.
45. Canaff L, Bevan S, Wheeler DG, Mouland AJ, Rehfuss RP, White JH et al (1998) Analysis of molecular mechanisms controlling neuroendocrine cell specific transcription of the chromogranin A gene. Endocrinology 139: 1184-1196.